Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Valproic acid (as semisodium valproate)

Brand: Depakote®
Indication: Manic episodes associated with bipolar disorder
Disease category: Central nervous system
Commissioning responsibility: CCG
PbR excluded: No


LMMG is adopting the local decision made prior to April 2013

Update March 2016 — there is a risk of abnormal pregnancy outcomes following maternal use. See DoH Drug Safety Alert (in supporting documents) for more information.


LMMG recommendation: Amber0
Click here to find the definitions for the colour classifications

Reason for decision:  The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Supporting documents:

MHRA Drug Safety Update - Medicines related to valproate: risk of abnormal pregnancy outcomes

MHRA Drug Safety Update - Valproate medicines (Epilim▼, Depakote▼): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met 

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG